Literature DB >> 19013457

Diminished iron concentrations increase adenosine A(2A) receptor levels in mouse striatum and cultured human neuroblastoma cells.

Seema Gulyani1, Christopher J Earley, Simonetta Camandola, Stuart Maudsley, Sergi Ferré, Mohamed R Mughal, Bronwen Martin, Aiwu Cheng, Marc Gleichmann, Byron C Jones, Richard P Allen, Mark P Mattson.   

Abstract

Brain iron insufficiency has been implicated in several neurological disorders. The dopamine system is consistently altered in studies of iron deficiency in rodent models. Changes in striatal dopamine D(2) receptors are directly proportional to the degree of iron deficiency. In light of the unknown mechanism for the iron deficiency-dopamine connection and because of the known interplay between adenosinergic and dopaminergic systems in the striatum we examined the effects of iron deficiency on the adenosine system. We first attempted to assess whether there is a functional change in the levels of adenosine receptors in response to this low iron. Mice made iron-deficient by diet had an increase in the density of striatal adenosine A(2A) (A(2A)R) but not A(1) receptor (A(1)R) compared to mice on a normal diet. Between two inbred murine strains, which had 2-fold differences in their striatal iron concentrations under normal dietary conditions, the strain with the lower striatal iron had the highest striatal A(2A)R density. Treatment of SH-SY5Y (human neuroblastoma) cells with an iron chelator resulted in increased density of A(2A)R. In these cells, A(2A)R agonist-induced cyclic AMP production was enhanced in response to iron chelation, also demonstrating a functional upregulation of A(2A)R. A significant correlation (r(2)=0.79) was found between a primary marker of cellular iron status (transferrin receptor (TfR)) and A(2A)R protein density. In conclusion, the A(2A)R is increased across different iron-insufficient conditions. The relation between A(2A)R and cellular iron status may be an important pathway by which adenosine may alter the function of the dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19013457      PMCID: PMC2784599          DOI: 10.1016/j.expneurol.2008.10.007

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  48 in total

1.  Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis.

Authors:  D D Mosser; A W Caron; L Bourget; C Denis-Larose; B Massie
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 2.  Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia.

Authors:  S Ferré; B B Fredholm; M Morelli; P Popoli; K Fuxe
Journal:  Trends Neurosci       Date:  1997-10       Impact factor: 13.837

3.  Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia.

Authors:  S H Kafka; R Corbett
Journal:  Eur J Pharmacol       Date:  1996-01-11       Impact factor: 4.432

Review 4.  Adenosine receptors: protein and gene structure.

Authors:  M E Olah; H Ren; G L Stiles
Journal:  Arch Int Pharmacodyn Ther       Date:  1995 Jan-Feb

5.  In vivo dopamine metabolism is altered in iron-deficient anemic rats.

Authors:  C Nelson; K Erikson; D J Piñero; J L Beard
Journal:  J Nutr       Date:  1997-12       Impact factor: 4.798

6.  Iron status and restless legs syndrome in the elderly.

Authors:  S T O'Keeffe; K Gavin; J N Lavan
Journal:  Age Ageing       Date:  1994-05       Impact factor: 10.668

Review 7.  Adenosine A2A receptors and neuroprotection.

Authors:  E Ongini; M Adami; C Ferri; R Bertorelli
Journal:  Ann N Y Acad Sci       Date:  1997-10-15       Impact factor: 5.691

8.  Effect of iron chelators on the transferrin receptor in K562 cells.

Authors:  K R Bridges; A Cudkowicz
Journal:  J Biol Chem       Date:  1984-11-10       Impact factor: 5.157

Review 9.  Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).

Authors:  Richard Allen
Journal:  Sleep Med       Date:  2004-07       Impact factor: 3.492

10.  Expression of xenotropic murine leukemia viruses as cell-surface gp70 in genetic crosses between strains DBA/2 and C57BL/6.

Authors:  H C Morse; T M Chused; J W Hartley; B J Mathieson; S O Sharrow; B A Taylor
Journal:  J Exp Med       Date:  1979-05-01       Impact factor: 14.307

View more
  13 in total

1.  Up-regulation of striatal adenosine A(2A) receptors with iron deficiency in rats: effects on locomotion and cortico-striatal neurotransmission.

Authors:  César Quiroz; Virginia Pearson; Seema Gulyani; Richard Allen; Christopher Earley; Sergi Ferré
Journal:  Exp Neurol       Date:  2010-04-10       Impact factor: 5.330

2.  Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome.

Authors:  César Quiroz; Seema Gulyani; Wan Ruiqian; Jordi Bonaventura; Roy Cutler; Virginia Pearson; Richard P Allen; Christopher J Earley; Mark P Mattson; Sergi Ferré
Journal:  Neuropharmacology       Date:  2016-09-04       Impact factor: 5.250

3.  Targeting hypersensitive corticostriatal terminals in restless legs syndrome.

Authors:  Gabriel Yepes; Xavier Guitart; William Rea; Amy H Newman; Richard P Allen; Christopher J Earley; César Quiroz; Sergi Ferré
Journal:  Ann Neurol       Date:  2017-12-07       Impact factor: 10.422

4.  Iron and restless legs syndrome: treatment, genetics and pathophysiology.

Authors:  James R Connor; Stephanie M Patton; Konrad Oexle; Richard P Allen
Journal:  Sleep Med       Date:  2016-11-10       Impact factor: 3.492

Review 5.  Brain-iron deficiency models of restless legs syndrome.

Authors:  Christopher J Earley; Byron C Jones; Sergi Ferré
Journal:  Exp Neurol       Date:  2022-06-30       Impact factor: 5.620

6.  Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome.

Authors:  Shangru Lyu; Mark P DeAndrade; Stefan Mueller; Alexander Oksche; Arthur S Walters; Yuqing Li
Journal:  Behav Brain Res       Date:  2019-07-31       Impact factor: 3.332

7.  Deficiency of Meis1, a transcriptional regulator, in mice and worms: Neurochemical and behavioral characterizations with implications in the restless legs syndrome.

Authors:  Shangru Lyu; Hong Xing; Yuning Liu; Pallavi Girdhar; Keer Zhang; Fumiaki Yokoi; Rui Xiao; Yuqing Li
Journal:  J Neurochem       Date:  2020-09-23       Impact factor: 5.372

8.  Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways.

Authors:  Ambreena Siddiq; Leila R Aminova; Carol M Troy; Kyungsun Suh; Zachary Messer; Gregg L Semenza; Rajiv R Ratan
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

Review 9.  Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System.

Authors:  Jonathan Janssens; Harmonie Etienne; Sherif Idriss; Abdelkrim Azmi; Bronwen Martin; Stuart Maudsley
Journal:  Front Endocrinol (Lausanne)       Date:  2014-09-01       Impact factor: 5.555

10.  Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome.

Authors:  Sergi Ferré; César Quiroz; Xavier Guitart; William Rea; Arta Seyedian; Estefanía Moreno; Verònica Casadó-Anguera; Manuel Díaz-Ríos; Vicent Casadó; Stefan Clemens; Richard P Allen; Christopher J Earley; Diego García-Borreguero
Journal:  Front Neurosci       Date:  2018-01-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.